China Resources Pharma (03320) has announced that its wholly-owned subsidiary, China Resources Pharmaceutical Holding Co., Ltd., has completed the issuance of the first tranche of its 2026 corporate bonds in China, with a total value of RMB 1.5 billion. The issuance was carried out under the approval of the China Securities Regulatory Commission (Approval No. 1457 [2025]), which granted permission for the subsidiary to issue up to RMB 10 billion in corporate bonds to qualified investors in China. The initial tranche of the 2026 corporate bonds carries a three-year term and an annual coupon rate of 1.65%. The net proceeds from the issuance will be allocated to productive expenditures, including the repayment of corporate debt, replenishment of working capital, project development and operational expenses, investments related to technological innovation, and other uses in compliance with applicable laws and regulations.